Genzyme, Hospira in manufacturing deal

Genzyme Corp. (NASDAQ:GENZ) said in an SEC filing that it had contracted Hospira Inc. (NYSE:HSP) to perform fill/finish for four products: Cerezyme imiglucerase for Gaucher's disease; Fabrazyme agalsidase beta for Fabry's disease; Myozyme alglucosidase alfa for Pompe's disease; and Thyrogen thyrotrophin alpha for thyroid cancer. The initial term of the deal expires in 2015 and includes automatic two-year extensions, unless terminated. Further terms were not disclosed. ...